ROCK1 and esophageal squamous cell carcinoma: Comparison with other ROCK1 inhibitors, dasabuvir offered more clinical possibilities with more available clinical safety data, which means we can conduct clinical trials to test the inhibitory effect of dasabuvir on ESCC especially patients who have HCV infection.